92 related articles for article (PubMed ID: 7124292)
1. Circulating TSH-binding inhibiting immunoglobulins in myasthenia gravis.
Kiessling WR; Finke R; Kotulla P; Schleusener H
Acta Endocrinol (Copenh); 1982 Sep; 101(1):41-6. PubMed ID: 7124292
[TBL] [Abstract][Full Text] [Related]
2. Thyroid function and circulating antithyroid antibodies in myasthenia gravis.
Kiessling WR; Pflughaupt KW; Ricker K; Haubitz I; Mertens HG
Neurology; 1981 Jun; 31(6):771-4. PubMed ID: 6787459
[TBL] [Abstract][Full Text] [Related]
3. [T3, T4, TSH and circulating antithyroglobulin antibodies in myasthenia gravis].
Kiessling WR; Pflughaupt KW; Haubitz I; Ricker K; Mertens HG
Endokrinologie; 1981 Oct; 78(1):67-72. PubMed ID: 7318778
[TBL] [Abstract][Full Text] [Related]
4. Thyroid response, especially to thyrotropin-binding inhibitory immunoglobulins, in euthyroid relatives of patients with Graves' disease: a clinical follow-up.
Tamai H; Kasagi K; Morita T; Hidaka A; Kuma K; Konishi J; Kumagai LF; Nagataki S
J Clin Endocrinol Metab; 1990 Jul; 71(1):210-5. PubMed ID: 1973421
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods.
Morris JC; Hay ID; Nelson RE; Jiang NS
Mayo Clin Proc; 1988 Jul; 63(7):707-17. PubMed ID: 2898572
[TBL] [Abstract][Full Text] [Related]
6. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
Brokken LJ; Wiersinga WM; Prummel MF
J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
[TBL] [Abstract][Full Text] [Related]
7. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
8. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
9. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
Chen W; Man N; Li YS; Shan ZY; Teng WP
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
[TBL] [Abstract][Full Text] [Related]
11. Thyroid-stimulating antibodies in patients with long-term remission of Graves' hyperthyroidism.
Hörmann R; Hobelsberger A; Saller B; Mann K
Klin Wochenschr; 1986 Oct; 64(21):1097-100. PubMed ID: 2879958
[TBL] [Abstract][Full Text] [Related]
12. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
[TBL] [Abstract][Full Text] [Related]
13. Precipitation of the thyrotropin receptor and identification of thyroid autoantigens using Graves' disease immunoglobulins.
Heyma P; Harrison LC
J Clin Invest; 1984 Sep; 74(3):1090-7. PubMed ID: 6088581
[TBL] [Abstract][Full Text] [Related]
14. Changes in thyroid volume during antithyroid drug therapy for Graves' disease and its relationship to TSH receptor antibodies, TSH and thyroglobulin.
Yamaguchi Y; Inukai T; Iwashita A; Nishino M; Yamaguchi T; Shohda Y; Shimomura Y; Ohshima K; Kobayashi S; Kobayashi I
Acta Endocrinol (Copenh); 1990 Oct; 123(4):411-5. PubMed ID: 1978459
[TBL] [Abstract][Full Text] [Related]
15. Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease.
Kashiwai T; Tada H; Watanabe Y; Shimaoka Y; Yagoro A; Hidaka Y; Fujikado T; Amino N
Thyroid; 1998 Oct; 8(10):881-5. PubMed ID: 9827654
[TBL] [Abstract][Full Text] [Related]
16. Possible binding site of thyrotropin binding inhibitor immunoglobulin (TBII) on the thyrotropin (TSH) receptor, which is different from TSH binding site.
Piraphatdist T; Sugawa H; Inoue D; Enomoto T; Mori T; Imura H
Biochem Biophys Res Commun; 1990 Oct; 172(2):529-36. PubMed ID: 1978673
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
Tamai H; Hirota Y; Kasagi K; Matsubayashi S; Kuma K; Iida Y; Konishi J; Okimura MC; Walter RM; Kumagai LF
J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the mouse thyrotrophin receptor with thyrotrophin binding inhibitor immunoglobulins.
Luttrell BM
J Endocrinol; 1983 Mar; 96(3):481-8. PubMed ID: 6131925
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of anti-TSH antibody in sera from patients with Graves' disease and other thyroid disorders.
Akamizu T; Mori T; Imura H; Noh J; Hamada N; Ito K; Koizumi Y; Yamada T; Fujihira T; Eto S
J Endocrinol Invest; 1989; 12(7):483-8. PubMed ID: 2571629
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
Hörmann R; Saller B; Müller R; Mann K
Klin Wochenschr; 1985 Dec; 63(24):1247-52. PubMed ID: 2868149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
